XTX Topco Ltd Purchases Shares of 11,285 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

XTX Topco Ltd purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,285 shares of the company’s stock, valued at approximately $451,000.

Other institutional investors also recently modified their holdings of the company. Citigroup Inc. increased its holdings in shares of Harmony Biosciences by 9.8% in the third quarter. Citigroup Inc. now owns 177,843 shares of the company’s stock valued at $7,114,000 after buying an additional 15,859 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Harmony Biosciences by 364.0% in the third quarter. HighTower Advisors LLC now owns 79,961 shares of the company’s stock valued at $3,199,000 after buying an additional 62,729 shares in the last quarter. Quest Partners LLC raised its stake in Harmony Biosciences by 137.6% during the 3rd quarter. Quest Partners LLC now owns 35,723 shares of the company’s stock valued at $1,429,000 after purchasing an additional 20,689 shares during the period. Marshall Wace LLP raised its stake in Harmony Biosciences by 145.4% during the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock valued at $9,220,000 after purchasing an additional 181,092 shares during the period. Finally, Rice Hall James & Associates LLC raised its stake in Harmony Biosciences by 42.1% during the 2nd quarter. Rice Hall James & Associates LLC now owns 80,512 shares of the company’s stock valued at $2,429,000 after purchasing an additional 23,867 shares during the period. Institutional investors own 86.23% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. UBS Group assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, September 10th. They set a “buy” rating and a $56.00 target price on the stock. Mizuho boosted their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, October 10th. Cantor Fitzgerald boosted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Needham & Company LLC reissued a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research note on Tuesday, October 29th. Finally, Oppenheimer reissued an “outperform” rating and set a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

Insider Buying and Selling

In related news, insider Jeffrey Dierks sold 21,496 shares of the company’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total value of $869,943.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 30.80% of the stock is currently owned by corporate insiders.

Harmony Biosciences Trading Up 1.7 %

NASDAQ HRMY opened at $32.39 on Friday. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.85 billion, a PE ratio of 15.35, a price-to-earnings-growth ratio of 0.60 and a beta of 0.79. The firm’s fifty day simple moving average is $34.32 and its 200-day simple moving average is $33.99.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.63 earnings per share. As a group, sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.36 earnings per share for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.